Thompson LL - Search Results

1

Three-word recall as a measure of memory.

Cullum CM, Thompson LL, Smernoff EN. Cullum CM, et al. Among authors: thompson ll. J Clin Exp Neuropsychol. 1993 Mar;15(2):321-9. doi: 10.1080/01688639308402566. J Clin Exp Neuropsychol. 1993. PMID: 8491854

2

Discriminability of the Wisconsin Card Sorting Test using the standardization sample.

Axelrod BN, Goldman RS, Heaton RK, Curtiss G, Thompson LL, Chelune GJ, Kay GG. Axelrod BN, et al. Among authors: thompson ll. J Clin Exp Neuropsychol. 1996 Jun;18(3):338-42. doi: 10.1080/01688639608408991. J Clin Exp Neuropsychol. 1996. PMID: 8877618

3

Contribution of the TPT to adult neuropsychological assessment: a review.

Thompson LL, Parsons OA. Thompson LL, et al. J Clin Exp Neuropsychol. 1985 Aug;7(4):430-44. doi: 10.1080/01688638508401275. J Clin Exp Neuropsychol. 1985. PMID: 4031026

4

The Ethics Code and neuropsychological assessment practices.

Binder LM, Thompson LL. Binder LM, et al. Among authors: thompson ll. Arch Clin Neuropsychol. 1995 Jan-Feb;10(1):27-46. Arch Clin Neuropsychol. 1995. PMID: 11653347 No abstract available.

5

Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade.

Asdourian MS, Shah N, Jacoby TV, Semenov YR, Otto T, Thompson LL, Dee EC, Reynolds KL, Chen ST. Asdourian MS, et al. Among authors: thompson ll. J Am Acad Dermatol. 2022 Jun 20:S0190-9622(22)01022-2. doi: 10.1016/j.jaad.2022.06.030. Online ahead of print. J Am Acad Dermatol. 2022. PMID: 35738514 No abstract available.

6

Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anti-cancer therapies: a multicenter retrospective study.

Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, LeBoeuf NR, Reynolds KL, Dewan AK, Chen ST. Asdourian MS, et al. Among authors: thompson ll. J Am Acad Dermatol. 2022 Jun 17:S0190-9622(22)01018-0. doi: 10.1016/j.jaad.2022.06.025. Online ahead of print. J Am Acad Dermatol. 2022. PMID: 35724890 No abstract available.

7

Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy.

Asdourian MS, Shah N, Jacoby TV, Thompson LL, Otto T, Semenov YR, Reynolds KL, Chen ST. Asdourian MS, et al. Among authors: thompson ll. J Am Acad Dermatol. 2022 May 13:S0190-9622(22)00807-6. doi: 10.1016/j.jaad.2022.05.015. Online ahead of print. J Am Acad Dermatol. 2022. PMID: 35577231 No abstract available.

8

Aberrant SKP1 Expression: Diverse Mechanisms Impacting Genome and Chromosome Stability.

Thompson LL, Rutherford KA, Lepage CC, McManus KJ. Thompson LL, et al. Front Cell Dev Biol. 2022 Mar 8;10:859582. doi: 10.3389/fcell.2022.859582. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35345853 Free PMC article. Review.

9

Association of pre-existing drug allergies with cutaneous immune-related adverse events among patients on immune checkpoint inhibitor therapy.

Jacoby TV, Otto TS, Asdourian MS, Shah N, Farcasanu M, Chang MS, Thompson LL, Reynolds KL, Chen ST. Jacoby TV, et al. Among authors: thompson ll. Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243. Online ahead of print. Br J Dermatol. 2022. PMID: 35290662 No abstract available.

10

Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors.

Chang MS, Jacoby TV, Otto TS, Shah N, Asdourian MS, Thompson LL, Reynolds KL, Chen ST. Chang MS, et al. Among authors: thompson ll. Eur J Cancer. 2022 May;166:21-23. doi: 10.1016/j.ejca.2022.01.032. Epub 2022 Mar 5. Eur J Cancer. 2022. PMID: 35259628 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results